stk-001
Nucleic acidexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 3, 2020 (NCT04442295)
Timeline
Indications
Studied for
Mechanism of action
- Sodium channel protein type I alpha subunitANTISENSE INHIBITOR
SCN1A antisense inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04740476 | Phase 2 | Jan 21, 2021 | Innovaderm, Stoke Therapeutics, Inc |
| NCT04442295 | Phase 1/Phase 2 (Phase 2) | Jun 3, 2020 | Innovaderm, Stoke Therapeutics, Inc |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Innovaderm | For profit | 2 | 0 | 1 | 2020 |
| Stoke Therapeutics, Inc | For profit | 2 | 2 | 1 | 2020 |
2 organizations
Page 1 / 1